NASDAQ:AXLA • US05454B2043
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AXCELLA HEALTH INC (AXLA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-02-16 | HC Wainwright & Co. | Maintains | Neutral |
| 2022-12-16 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-12-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-11-02 | Chardan Capital | Maintains | Buy |
| 2022-10-03 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-03 | SVB Leerink | Maintains | Outperform |
| 2022-08-03 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-09 | Chardan Capital | Maintains | Buy |
| 2021-11-16 | Chardan Capital | Maintains | Buy |
| 2021-10-12 | Noble Capital Markets | Initiate | Outperform |
| 2021-09-22 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-07-30 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-07-06 | HC Wainwright & Co. | Initiate | Buy |
| 2021-06-03 | Chardan Capital | Maintains | Buy |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 277.21% | |||||||
| EBITDA YoY % growth | -27.53M | -32.83M -19.25% | -56.78M -72.95% | -53.42M 5.92% | -61.56M -15.24% | -72.39M -17.59% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.92M | -33.9M -17.22% | -57.44M -69.44% | -53.84M 6.27% | -61.85M -14.88% | -72.8M -17.70% | N/A 78.42% | N/A -0.57% | N/A -3.84% | N/A -338.15% | N/A -43.36% | N/A 0.22% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -4.81 | -1.87 61.12% | -12.73 -580.75% | -38.25 -200.47% | N/A 86.67% | N/A | N/A -5.00% | N/A -319.05% | N/A -39.77% | N/A 3.25% |
All data in USD
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.28 85.00% | -1.28 84.55% | -1.28 -2.00% | -1.28 -2.00% | -1.28 | -1.28 |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.908M 77.14% | -3.919M 76.62% | -3.931M 5.96% | -3.943M -11.39% | -3.956M -1.23% | -3.967M -1.22% |
All data in USD
8 analysts have analysed AXLA and the average price target is 15870.1 USD. This implies a price increase of 346408.73% is expected in the next year compared to the current price of 4.58.
AXCELLA HEALTH INC (AXLA) will report earnings on 2024-03-28, after the market close.
The consensus EPS estimate for the next earnings of AXCELLA HEALTH INC (AXLA) is -1.27 USD and the consensus revenue estimate is 0 USD.